1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
TUMOUR ASSOCIATED IMMUNITY AND IMMUNOCOMPETENCE IN OVARIAN CANCER
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1976.tb00850.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 83, Issue 5, pages 393–394, May 1976
Additional Information
How to Cite
Levin, L., Mchardy, J. E., Poulton, T. A., Curling, O. M. and Hudson, C. N. (1976), TUMOUR ASSOCIATED IMMUNITY AND IMMUNOCOMPETENCE IN OVARIAN CANCER. BJOG: An International Journal of Obstetrics & Gynaecology, 83: 393–394. doi: 10.1111/j.1471-0528.1976.tb00850.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Abstract
- References
- Cited By
Summary
Cell-free extracts of autologous ovarian cancer cells evoked a delayed hypersensitivity response (DHR) in skin in four out of six patients in remission from disease and none of seven patients in relapse. These initial results appear to be consistent with in vitro blastogenic assay using the same autologous extracts. To assess whether diminished tumour-associated immunity was due to impaired cellmediated immunocompetence, blastogenic responses to purified protein derivative of tuberculin (PPD), a secondary recall antigen, and phytohaemagglutinin (PHA) were assessed. Impaired responses to PHA were seen in the relapse group of patients, but responses to PPD did not appear to be impaired in this group.